Our pipeline of immune-modulating, clinical-stage product candidates are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation.

Program & Target Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3 Mkt Rights
Rilonacept IL-1α & IL-1β Recurrent Pericarditis
(breakthrough therapy designation)
Mid Phase 3
Worldwide (excluding the Middle East and North Africa)
Mavrilimumab GM-CSFRα Giant Cell Arteritis Phase 2
CAR T Induced Cytokine Release Syndrome* End Phase 1
COVID-19 Pneumonia & Hyperinflammation End Phase 1
Vixarelimab OSMRβ Prurigo Nodularis Phase 2
Diseases Characterized by Chronic Pruritus Phase 2
KPL-404 CD40 T-Cell Dependent, B-Cell–Mediated Indications Phase 1
*Clinical collaboration with Kite, a Gilead Company, in relapsed or refractory large B-cell lymphoma. Phase 2 trial expected to start in the second half of 2020. Kite will be the sponsor of the trial and will be responsible for its conduct.
Preparing for a potential registrational development program for mavrilimumab in COVID-19 pneumonia and hyperinflammation.

Every Second Counts!